retatrutide ada 2025 results Retatrutide: The Unapproved Drug America Already Takes Back in 2023 we saw

Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss this with their clinical team before enrolling in any trial involving this drug class

A growing share of large self-funded employer plans administered by Aetna removed weight-loss medication coverage at 2026 plan-year renewal check your specific employer's benefit summary

Researchers should consult the primary NEJM 2023 paper and relevant institutional ethics frameworks

What makes retatrutide stand out from other drugs

If medically appropriate, the provider may prescribe weight loss medications and recommend lifestyle strategies tailored to your needs